Foghorn Therapeutics (FHTX) Earnings Analysis
Foghorn Therapeutics (FHTX) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.29 USD vs -0.28 USD est (-3.6%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -4.45.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does FHTX next report earnings?
No confirmed upcoming earnings date is currently scheduled for FHTX. This page updates as the calendar is published.
FHTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.29 USD | -0.28 USD | -3.6% | Miss |
| 2026-03-11 | -0.34 USD | -0.28 USD | -21.4% | Miss |
| 2025-03-06 | -0.3 USD | -0.43 USD | +30.2% | Beat |
| 2024-11-04 | -0.31 USD | -0.42 USD | +26.2% | Beat |
| 2024-08-08 | -0.45 USD | -0.6 USD | +25% | Beat |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
FHTX valuation and analyst view
| Trailing P/E | -4.45 |
|---|---|
| Trailing EPS | -1.08317 USD |
| Price / book | -4.74 |
| Dividend yield | 0.00% |
| Market cap | 0.30B |
| Analyst consensus | Buy (8 buy / 1 hold / 0 sell) |
| Avg price target | 11.67 USD |
Related research pages
Frequently asked questions
When is Foghorn Therapeutics (FHTX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for FHTX. This page updates as the calendar is published.
Did FHTX beat earnings last quarter?
In its 2026-05-07 report, FHTX posted EPS of -0.29 USD versus a -0.28 USD estimate — a miss of 3.6%.
What is FHTX's earnings track record?
Over the last 5 reported quarters with consensus data, FHTX beat estimates 3 times (60%).
What is FHTX's current P/E ratio and EPS?
FHTX trades at a trailing P/E of -4.45 on trailing EPS of -1.0831739827718045 USD.
What do analysts rate FHTX?
Analyst consensus is "Buy" across 9 ratings (0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 11.67 USD.